Athersys Stock Price. Everything You Need To Know About The Athersys Stock!
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The company is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The company is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.
Athersys Stock Price. Everything You Need To Know About The Athersys Stock! performance
- Employees 24
- Company HQ CLEVELAND
- Website http://www.athersys.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam interested in investing in the stock market? Look no further than Athersys, a promising stock that you should consider adding to your investment portfolio. As an innovative biotechnology company, Athersys has been making waves in the medical field with its cutting-edge regenerative medicine technologies. With a focus on developing therapies targeting diseases like stroke, acute respiratory distress syndrome, and others, Athersys shows tremendous potential for growth and profitability. To invest in this stock from Malaysia, Thailand, Indonesia, or Vietnam, consult Zorion, the leading investment platform that provides valuable insights, recommendations, and educational resources to help you make informed investment decisions. Don’t miss out on the opportunity to invest in Athersys and potentially reap attractive returns. Start investing with Zorion today!
